Page 1

Press release • • . • • . Ma Pât MaaT Pharma Publishes its Half - Year 2026 Results and Provides a Business Update Maa T013 ( XervytegⓇ ) : . • In September 2026 , following the re - examination procedure , the CHMP maintained its negative opinion on the Conditional Marketing Authorization Application ( MAA ) for MaaT013 ( Xervyteg® ) . Feedback received through a Type C interaction with the U.S. Food and Drug Administration ( FDA ) contributes to the preparation of PHOENIX as a proposed registrational Phase 3 trial and provides a framework for finalizing the protocol and progressing U.S. development activities . MaaT034 : CMC - focused pre - Investigational New Drug ( IND ) meeting with the U.S. FDA , focused on CMC ( Chemistry , Manufacturing and Controls ) activities , scheduled for October 2026 . Revenue of € 1.1 million in H1 2026 , compared with € 2.4 million in H1 2025 , mostly driven by the impact of the Clinigen Licensing Agreement as of January 1 , 2026 , while patient demand in the Early Access Program ( EAP ) remained globally stable . Cash and cash equivalents of € 17.1 million as of June 30 , 2026 . Cash runway now estimated to extend to December 2026 based on the Company's current operating plan . The Company is exploring financing opportunities from investors and strategic partnerships Lyon , France , September 29 , 2026 , 6:00 p.m. CET - MaaT Pharma ( EURONEXT : MAAT - the " Company " ) , a clinical - stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ™ ( MET ) dedicated to enhancing survival for patients with cancer through immune modulation , today announced its half - year financial results for the six - month period ended June 30 , 2026 , and provided a business update . 1/6 16